PROVIDE
Completed study Official Study Title A Personalized Randomized Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis (PROVIDE) Brief Description PROVIDE is a randomized clinical trial aiming to the personalized therapy of patients at septic shock. Using biomarkers, enrolled patients are randomized through a double-dummy approach to immunotherapy or placebo
ACTIVATE
Completed study Official Study Title A randomized Clinical Trial for enhanced trained Immune responses through bacillus calmette-guérin VAccination to prevenT infections of the Elderly (ACTIVATE) Brief Description ACTIVATE is a randomized clinical trial aiming to investigate if the developing concept of trained immunity i.e. the memory of the innate immune system coming after vaccination
INCLASS
Completed study Official Study Title A double-blind, randomized, placebo-controlled clinical study of the efficacy of INtravenous CLArithromycin as adjunctive treatment in patients with Sepsis and respiratory and multiple organ dysfunction Syndrome Brief Description INCLASS is a randomized clinical trial aiming to compare the efficacy of intravenous clarithromycin over placebo in patients with sepsis and
PROGRESS
Completed study Official Study Title A randomized prospective clinical trial to assess the role of PROcalcitonin-Guided antimicrobial therapy to REduce long-term infectionS Sequelae Brief Description PROGRESS is a randomized clinical trial aiming to test the efficacy of an algorithm of the duration of antimicrobial treatment based on serum procalcitonin in patients with sepsis on
IFX-1-P2.3
Completed study Official Study Title An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa Details Status: Completed Study Type: Interventional (Clinical Trial) Study phase: II Study sites: 1 site in Greece Actual enrolment: 12 participants ClinicalTrials.gov Identifier: NCT03001622 EudraCT number: 2016-002988-33 National
HIDRA04
Completed study Official Study Title A double-blind, randomised, placebo-controlled clinical trial of the safety and efficacy of MABp1, a- first-in-class true human antibody targeting interleukin-1alpha, in patients with hidradenitis suppurativa not eligible for adalimumab Brief Description HIDRA04 is a double-blind randomized study aiming to the comparison of the efficacy of MABp1 (Bermekimab), a fully